Industry Briefs: December 10, 2012
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.
Company News
Amorfix Life Sciences has established a collaboration with CNJ Holdings, a wholly owned subsidiary of Cangene, for the identification and development of therapeutic antibodies against proprietary disease specific epitopes identified using Amorfix’s ProMIS discovery technology for treating various oncology indications. Read More
AMRI has extended its commercial supply relationship with GE Healthcare for aminobisamide hydrochloride. Read More
Impact Analytical announced an expansion that includes new testing and analysis laboratories. The project is scheduled to be completed by March 2013. Read More
Kemwell has signed an agreement with Mercury Pharma for the manufacturing of pharmaceuticals at its new production facility in Uppsala, Sweden. Read More
Sartorius Stedim Biotech has launched its Sartoguard NF prefilter series, featuring a combination of high-performance polyethersulfone membranes and nanofleece technology. Read More
People News
AAIPharma has appointed Timothy Rhines as senior director of biopharmaceutical Development. Read More
In addition, AAIPharma has also appointed David Browne director of analytical chemistry. Read More
AmerisourceBergen has named Peyton R. Howell senior vice-president of AmerisourceBergen Corporation, and president of global sourcing and manufacturer relationships. Read More
Pfizer has elected CEO Ian Read as chairman of the board. Read More
Roche has announced several changes to its board of directors, and has proposed CEO Severin Schwan as a new member of the board. Read More
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
